In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights key interviews with Philips’ CEO Roy Jakobs on NAM’s draft framework on AI, BD’s CTO Beth McCombs R&D initiatives and HSS spine co-chair Sheeraz Qureshi on his vision for integrating AI tech. Hannah Daniel discusses the FDA’s new initiative to create an idea lab for medical device use at home and Apple Watch’s new feature to help people with Parkinson’s disease. Listen to the podcast via the player...

Flora and Emma are joined by Datamonitor’s CNS analysts Summer, Joseph, and Wen-Yu to discuss coverage from AAN. Other platforms (in addition to SoundCloud):​ Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836​ Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz​ TuneIn -...

Audio roundup of selected biopharma industry content from Scrip over the business week ended 26 April 2024. In this episode: 2023’s top selling drugs and the COVID cliff; falling sales force Roche to reassess priorities; Phase III immunology win for Sanofi; BMS’s strong pipeline: and which companies could be acquired next. https://scrip.citeline.com/SC150182/Quick-Listen-Scrips-Five-MustKnow-Things

2024 Global Generics & Biosimilars Awards by Citeline

Learn how molecular technology is enhancing patient safety for CAR-T clinical trials. US FDA recently initiated class safety labeling changes after evaluating the safety of CAR-T cancer treatment therapies. What does this mean for developers in the CAR-T landscape? Listen to your free podcast to find out. Listen in on the conversation as experts from Cerba discuss facilitating patient safety measures in CAR-T therapies by accurately identifying the integration of viral vectors, utilizing...

Pink Sheet reporter and editors discuss the impact of FDA biosimilar promotion guidance on the future of the interchangeability designation (:34), upcoming guidance on accelerated approval for gene therapies (14:15), and partisan attacks on the agency from Capitol Hill (27:13). More On These Topics From The Pink Sheet Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says:...

Pulmonologist Bing Xue, MD, reviews the latest GOLD guidelines and discusses relevant topics regarding COPD treatment.

Join Scrip's China-based editors Brian Yang and Dexter Yan in this Chinese/English podcast as they look at data presented to AACR by Chinese pharma firms and recent acquisitions of China-based companies. UK-based writer Andrew McConaghie also joins to provide his perspectives, including on the proposed US BIOSECURE Act. https://scrip.citeline.com/SC150164/China-Biotech-Podcast-AACR-BIOSECURE-European-Perspectives

Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.

Citeline - Cerba Research Podcast V2 by Citeline

Scrip's Joseph Haas, Kevin Grogan and Edwin Elmhirst talk about the biopharma M&A environment and which companies might look particularly appealing to potential acquirers.

In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.

Helping Consumers ‘Tune In’ To Reliable Health Information, With Kaizo’s Anita Nahal “Consumers are rewriting the rules when it comes to where they are going for information and the type of information they are looking for,” reports Kaizo’s Anita Nahal, speaking to HBW Insight’s Over the Counter podcast about the agency’s latest Communicating Health Messages report. Trust in social media has increased, and personal beliefs and lived experiences are playing a larger role in shaping attitudes...

Audio roundup of selected biopharma industry content from Scrip over the business week ended 19 April 2024. In this episode: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs. https://scrip.citeline.com/SC150134/Quick-Listen-Scrips-Five-MustKnow-Things Other podcasts in this series: https://on.soundcloud.com/xSKGyTJnAYS66apP9

Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi (:28), Janet Woodcock’s new post-FDA role (12:28), and ongoing preparations for new pneumococcal vaccines that will reach the market soon (17:28). #business #pharma More On These Topics From The Pink Sheet Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs:...

A new diagnostic technology to screen and triage individuals based on breath.

Scrip’s senior editor Vibha Ravi speaks with Jack Hoppin, CEO and chairman, and John Babich, chief scientific officer, at Ratio Therapeutics, about the company’s radiopharmaceuticals pipeline, investment by BMS, use of AI, trends and developments in radiopharma research like combining ADCs or PARP inhibitors and more. https://scrip.citeline.com/SC150098/Ratio-Therapeutics-On-BMS-Investment-Radiopharma-RD-Trends-AI-Use

In this Chinese- and English-language episode, guest speaker Treehill Partners co-founder Ali Parshadezah joins Brian Yang and Dexter Yan to discuss updates on the proposed US BIOSECURE Act and US-China biotech movements, including recent M&A activity. https://scrip.citeline.com/SC150090/China-Biotech-Podcast-BIOSECURE-Updates-GenmabProfound-Deal

Audio roundup of selected biopharma industry content from Scrip over the business week ended 12 April 2024. In this episode: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer. https://scrip.citeline.com/SC150097/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporter and editors discuss Richard Pazdur’s call for more diverse opinions in FDA advisory committee meeting open public hearings (:36), agency questions about the stakeholders sponsors consult to execute clinical trial diversity plans (20:52), and Stealth BioTherapeutics’ application for the Barth Syndrome candidate elamipretide getting reviewed (32:23). More On These Topics From The Pink Sheet Adcomm Open Public Hearings Have Become Too Sponsor-Driven – US FDA's Pazdur:...

In this episode, In Vivo speaks to 2024 Rising Leader Hanadie Yousef, CEO of Juvena Therapeutics, about her journey, the secretome as a source of therapeutics, longevity medicine and alternatives to GLP-1 inhibitors for obesity.

Audio roundup of selected biopharma industry content from Scrip over the business week ended 5 April 2024. In this episode: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda. https://scrip.citeline.com/SC150062/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed (:32), an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees (9:08), and Japan’s PMDA opening an office in Washington D.C. (16:19). More On These Topics From The Pink Sheet Amylyx’s Relyvrio Withdrawal May Trigger More Public Pledges Based On Confirmatory Trial Data:...

In this episode, Medtech Insight regulatory reporter Hannah Daniel speaks to industry professionals at the Healthcare Information and Management Systems Society (HIMSS) 2024 conference about what they enjoy about the annual gathering and what excites them for the future.